EUCTR2005-003166-42-DE进行中（未招募）不适用
Palliative Chemotherapy (2nd line) with Imatinib (GlivecTM) in Patients with Bile Duct Cancer. - GlivecGG
niversity of Leipzig0 个研究点目标入组 40 人开始时间: 2005年9月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •There must be a two-dimensional detectable tumor or metastasis, patient`s age must be between 18 and 75 years, patient`s general condition must be WHO < 2, live expectancy must be at least 3 months, and there must be an informed consent. Moreover, bilirubin must not be elevated more than 1 times (1.5 times in the presense of liver metastases) and ALT/AST more than 1.5 times (2.5 times in the presense of liver metastases) of the upper normal value. Creatinine must be < 133 umol/l (< 1,5 mg/dl) and creatinine clearance must be > 60 ml/min.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnant and lactating women, fertile men and women without adequate contraception, patients without a primary chemotherapy, tumor extent >50% of the liver or >25% of the lung, abdominal mass >10cm, CNS-metastases, ileus, non-measurable tumor extent, known intolerance to imatinib and its preservatives, second malignancy, second unstable disease, comedication with non-approved drugs, any other anti-cancer treatment, comedication with paracetamol.
研究者
相似试验
已完成
不适用
Palliative Chemotherapy (2nd line) with Imatinib (Glivec™) in Patients with Bile Duct Canceron-resectable bile duct cancerBile duct cancerCancerISRCTN32669229niversity of Leipzig (Germany)40
已完成
2 期
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionNCT00039377National Cancer Institute (NCI)58
招募中
2 期
Phase II trial using imatinib combined with chemotherapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)ewly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)JPRN-UMIN000001226Japan Adult Leukemia Study Group66
进行中（未招募）
1 期
Chemotherapy with gemcitabine, capecitabine, irinotecan and bevacizumab to patients with cholangiocarcinoma after progression on first line treatment.patients with cholangiocarcinoma after progression. When patients with cholangiocarcinoma cannot be operated, we cannot cure them. The purpose of oncologic treatment is to prolong survival and to enhance quality of life. When first line treatment fails, we do not have a standard treatment for these patients. Many of the patients are still in a good condition and we hope for this group that our treatment can main stain their good condition and prolong survivalreatment.MedDRA version: 14.1Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2013-001559-11-DKHerlev University Hospital50
进行中（未招募）
1 期
SecOnd-line Chemotherapy with RAmucirumab +/- pacliTaxel in Elderly advanced gastric or gastroesophageal junction cancer patientsElederly patient with advanced gastric or gastroesophageal junction cancer, after first line chemotherapyMedDRA version: 20.0Level: LLTClassification code 10042080Term: Stomach cancerSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10042088Term: Stomach cancer stage IV with metastasesSystem Organ Class: 100000004864EUCTR2017-001683-37-FRFédération Francophone de Cancérologie Digestive112